<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001061</url>
  </required_header>
  <id_info>
    <org_study_id>Misoprostol abortion</org_study_id>
    <nct_id>NCT05001061</nct_id>
  </id_info>
  <brief_title>Sublingual vs Vaginal Misoprostol for Termination of First Trimesteric Missed Abortion</brief_title>
  <official_title>Sublingual vs Vaginal Misoprostol for Termination of First Trimesteric Missed Abortion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of sublingual versus vaginal misoprostol in termination of first trimester missed&#xD;
      abortion&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      study will be made on female patients with first trimester missed abortion confirmed by&#xD;
      ultrasound . Participants will be divided into 2 groups one group (A) will receive sublingual&#xD;
      Misoprostol and the other group(B) will receive vaginal Misoprostol as a 800 micro grams&#xD;
      every 4 hours in both groups up to five doses the aim of the study is to compare efficay of&#xD;
      sublingual and vaginal Misoprostol in complete termination of first trimester missed abortion&#xD;
      and which route is the best will less side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 3, 2021</start_date>
  <completion_date type="Anticipated">October 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurance of complete abortion within 24 hours with Misoprostol drug</measure>
    <time_frame>Within 24 hours</time_frame>
    <description>Efficacy of sublingual and vaginal Misoprostol in complete termination of first trimester missed abortion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Which route is the best and less side effects in complete termination of first trimester missed abortion by Misoprostol drug</measure>
    <time_frame>within 24 hours</time_frame>
    <description>Vaginal versus sublingual route of administration of Misoprostol for complete termination of first trimester missed abortion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>Sublingual Misoprostol for termination of first trimester missed abortion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients diagnosed as first trimester missed abortion will receive sublingual Misoprostol 800 micrograms every 4 hours up to five doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol for termination of first trimester missed abortion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients diagnosed as first trimester missed abortion will receive vaginal Misoprostol 800 micrograms every 4 hours up to five doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol Pill</intervention_name>
    <description>sublingual versus vaginal Misoprostol in termination of first trimester missed abortion</description>
    <arm_group_label>Sublingual Misoprostol for termination of first trimester missed abortion</arm_group_label>
    <arm_group_label>Vaginal Misoprostol for termination of first trimester missed abortion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with an ultrasound diagnosis of missed abortion &lt; 13 weeks gestation without any&#xD;
             clinical criteria of Inevitable abortion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refused the medical treatment.&#xD;
&#xD;
          -  Patients have contraindications of the drug (Misoprostol).&#xD;
&#xD;
          -  Missed abortion associated with any signs of sepsis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Emam</last_name>
    <phone>01003304781</phone>
    <email>emam3882@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Allameh Z, Goharian M, Eslamian M. Effect of misoprostol with and without letrozole on the induction of abortion for women with first-trimester missed abortion. Int J Gynaecol Obstet. 2020 Nov;151(2):214-218. doi: 10.1002/ijgo.13326. Epub 2020 Sep 1.</citation>
    <PMID>32700359</PMID>
  </reference>
  <reference>
    <citation>Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S160-7. Epub 2007 Oct 26. Review.</citation>
    <PMID>17963768</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahmoud Emam Ahmed</investigator_full_name>
    <investigator_title>Resident in obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

